The document discusses the safety and supply of plasma-derived hemophilia products. It outlines how fractionation advances in the 1960s-1970s enabled treatment to free hemophiliacs. Both plasma-derived and recombinant products are important, with no single supply sufficient. Industry standards have reduced pathogen risks through donor selection, testing, and viral clearance steps. Emerging pathogens like West Nile virus require ongoing vigilance. While risks are low, vCJD transmission through plasma products remains a concern addressed through geographic deferrals and manufacturing clearance. Increasing global product demand challenges adequate supply for all patients.